Alex Hanly – CEO – Lithium Universe (ASX:LU7) objective is to construct a Lithium Project in Québec with utmost speed, and to assist Canada facilitate the transition towards cleaner energy.
Copyright 2023 – Finance News Network
Source: Finance News Network
21 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
Read More30 Jul 2024 - Andrew Penkethman - CEO & Managing Director - Ardea Resources (ASX:ARL) is an ASX-listed nickel resources company, with a large portfolio of 100%-controlled West Australian-based projects.
Read More21 Oct 2019 - Kingston Resources Limited (ASX:KSN) CFO, Chris Drew, provides an update on the company's Misima and Livingstone gold projects and drill program.
Read More15 Feb 2022 - Imdex (ASX:IMD) CEO Paul House discusses drivers behind the company's 1H22 performance, research and development, and outlook.
Read More30 Jul 2024 - Cristian Moreno - Managing Director - Torque Metals (ASX:TOR) is an exploration company with a proven discovery methodology, combining drilling results with machine learning algorithms and geological interpretation.
Read More13 Dec 2023 - Chilwa Minerals Limited (ASX:CHW) Managing Director Cadell Buss discusses surprising drilling results and outlines future exploration plans.
Read More03 Jun 2021 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses the company's growth strategy, outlook and its product suite for supporting employee communication and collaboration.
Read More12 Aug 2020 - Centuria Capital Group (ASX:CNI) Joint CEO John McBain discusses full year 2020 results, acquisition of Augusta Capital, and guidance for FY21.
Read More21 Sep 2023 - Managing Director of Pacgold Limited (ASX:PGO) Tony Schreck discusses the company's key asset the Alice River Gold Project.
Read More27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
Read More
